🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Genkyotex advancing PBC candidate GKT831, Phase 2 data readout in coming months

Published 08/27/2018, 01:01 PM
© Reuters.  Genkyotex advancing PBC candidate GKT831, Phase 2 data readout in coming months
ARNA
-
ICPT
-
ENTA
-
TVTX
-
CBAY
-
  • French biotech Genkyotex announces the completion of enrollment 90 subjects necessary for an interim analysis in its Phase 2 clinical trial evaluating lead candidate GKT831 in patients with primary biliary cholangitis (PBC). Preliminary results, expected this fall, will be assessed when patients have completed six weeks of dosing.
  • The 24-week, double-blind, placebo-controlled study will enroll a total of102 PBC patients who have not responded adequately to ursodeoxycholic acid (UDCA). Participants will be randomized into three arms: UDCA + placebo, UDCA + GKT831 400 mg daily and UDCA + GKT831 400 mg twice daily.
  • GKT831 inhibits a family of enzymes called NOX, oxidases that are associated with diseases like atherosclerosis, hypertension, cancer and endocrine disorders.
  • PBG-related tickers: CBAY, ICPT, ARNA, ENTA, RTRX
  • Now read: Genfit And Elafibranor In NASH Fibrosis: A Revisit Of The FDA Guidelines


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.